Last reviewed · How we verify
etoricoxib 60mg
At a glance
| Generic name | etoricoxib 60mg |
|---|---|
| Also known as | pregabalin 75mg |
| Sponsor | Muhammad Ilyas |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination (PHASE4)
- Biomarkers for Prediction of Analgesic Efficacy in Knee OA. (NA)
- Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib (EARLY_PHASE1)
- Pulse Shortwave Therapy in Cervical Osteoarthritis (NA)
- Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer (PHASE2)
- Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty (PHASE4)
- Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy (PHASE3)
- Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- etoricoxib 60mg CI brief — competitive landscape report
- etoricoxib 60mg updates RSS · CI watch RSS
- Muhammad Ilyas portfolio CI